SAFETY AND EFFICACY OF A PERI-OPERATIVE PROTOCOL FOR PATIENTS WITH DIABETES TREATED WITH CONTINUOUS SUBCUTANEOUS INSULIN INFUSION WHO ARE ADMITTED FOR SAME-DAY SURGERY

被引:21
|
作者
Sobel, Sandra I. [1 ]
Augustine, Marilyn [2 ]
Donihi, Amy C. [3 ]
Reider, Jodie [1 ]
Forte, Patrick [4 ]
Korytkowski, Mary [1 ]
机构
[1] Univ Pittsburgh, Dept Med, Div Endocrinol & Metab, Pittsburgh, PA USA
[2] Univ Rochester, Med Ctr, Dept Med, Div Endocrinol & Metab, Rochester, NY 14642 USA
[3] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA
[4] Univ Pittsburgh, Med Ctr, Dept Anesthesiol, Pittsburgh, PA USA
关键词
PUMP THERAPY; AMERICAN ASSOCIATION; NONCARDIAC SURGERY; MANAGEMENT; DEXAMETHASONE; HYPERGLYCEMIA; STATEMENT; OUTCOMES;
D O I
10.4158/EP15727.OR
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The number of people with diabetes using continuous subcutaneous insulin infusions (CSII) with an insulin pump has risen dramatically, creating new challenges when these patients are admitted to the hospital for surgical or other procedures. There is limited literature guiding CSII use during surgical procedures. Methods: The study was carried out in a large, urban, tertiary care hospital. We enrolled 49 patients using insulin pump therapy presenting for 57 elective surgeries. We developed a CSII peri-operative glycemic management protocol (PGMP) to standardize insulin pump management in patients admitted to a same-day surgery unit (SDSU). The purpose was evaluate the safety (% capillary blood glucose (CBG) <70 mg/dL and/or pump incidents) and efficacy (first postoperative CBG <= 200 mg/dL) of the CSII PGMP. We determine the contribution of admission CBG, type of anesthesia, surgery length, and peri-operative steroid use on postoperative glycemic control. Results: Overall, 63% of patients treated according to the CSII PGMP had a first postoperative CBG <= 200 mg/dL. There were no episodes of intra-or postoperative hypoglycemia. For patients treated with the CSII PGMP, the mean postoperative CBG was lower in patients with anticipated or actual surgical length <= 120 minutes (158.1 +/- 53.9 vs. 216 +/- 77.7 mg/dL, P<.01). No differences were observed with admission CBG, type of anesthesia, or steroid use. Conclusions: This study demonstrates that a CSII PGMP is both safe and effective for patients admitted for elective surgical procedures and provides an example of a standardized protocol for use in clinical practice.
引用
收藏
页码:1269 / 1276
页数:8
相关论文
共 50 条
  • [21] Bariatric surgery results in patients with type 1 diabetes mellitus on continuous subcutaneous insulin infusion therapy
    Moreno-Fernandez, Jesus
    Chico, Ana
    ENDOCRINOLOGIA Y NUTRICION, 2016, 63 (10): : 571 - 572
  • [22] Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion
    Thethi, Tina K.
    Rao, Ajay
    Kawji, Haytham
    Mallik, Tilak
    Yau, C. Lillian
    Christians, Uwe
    Fonseca, Vivian
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2010, 24 (02) : 73 - 78
  • [23] Clinical value of Flash glucose monitoring in patients with type 1 diabetes treated with continuous subcutaneous insulin infusion
    Moreno-Fernandez, Jesus
    Pazos-Couselo, Marcos
    Gonzalez-Rodriguez, Maria
    Rozas, Pedro
    Delgado, Manuel
    Aguirre, Miguel
    Manuel Garcia-Lopez, Jose
    ENDOCRINOLOGIA DIABETES Y NUTRICION, 2018, 65 (10): : 556 - 563
  • [24] BETTER METABOLIC OUTCOME AND PATIENT SATISFACTION IN PATIENTS WITH TYPE 1 DIABETES TREATED WITH CONTINUOUS SUBCUTANEOUS INSULIN INFUSION
    Gjessing, H. J.
    Jorgensen, U. L.
    Pedersen, J.
    Moller, C. C.
    Grodum, E.
    Schousboe, K.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2013, 15 : A39 - A39
  • [25] Usefulness of a New Technology Unit creation for continuous subcutaneous insulin infusion treated type 1 diabetes patients
    Moreno-Fernandez, Jesus
    Seco Segura, Angela M.
    Rozas Moreno, Pedro
    Delgado del Rey, Manuel
    Gonzalez Gonzalez, Abel
    Aguirre Sanchez-Covisa, Miguel
    AVANCES EN DIABETOLOGIA, 2014, 30 (03): : 87 - 89
  • [26] The Impact of Continuous Subcutaneous Insulin Infusion Therapy on Efficacy and Safety in a Cohort of Type 1 Diabetes Patients: A 3-Year Prospective Study
    Melidonis, Andreas
    Kamaratos, Alexandros
    Angelidi, Angeliki
    Thomakos, Petros
    Vrakas, Spiridon
    Bakalis, John
    Fousteris, Evangelos
    Iraklianou, Stella
    DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 (03) : 159 - 163
  • [27] Safety and efficacy of a pharmacist-driven protocolized transition from insulin infusion to subcutaneous insulin in patients undergoing cardiothoracic surgery
    Bird, Shaina A.
    Thuyns, Michael R.
    JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 2025, 8 (02): : 123 - 128
  • [28] Safety and efficacy of an outpatient program for the initiation of continuous subcutaneous insulin infusion (CSII) pump therapy in a pediatric diabetes program.
    DeClue, TJ
    Lin, TH
    Rogert, C
    JOURNAL OF INVESTIGATIVE MEDICINE, 1999, 47 (02) : 132A - 132A
  • [29] Efficacy & safety of transitioning from continuous insulin infusion (CII) to an insulin glargine based regimen in cardiovascular surgery patients
    Liebl, Michael G.
    Nguyen, Phuong H.
    Hamilton, Dale
    CRITICAL CARE MEDICINE, 2007, 35 (12) : A135 - A135
  • [30] MORPHOLOGICAL FINDINGS IN PLACENTAS OF PATIENTS WITH TYPE-I (INSULIN-DEPENDENT) DIABETES TREATED BY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII)
    LAURINI, RN
    VISSER, GHA
    VANBALLEGOOIE, E
    KOITER, TR
    NETHERLANDS JOURNAL OF MEDICINE, 1986, 29 (02): : 67 - 67